EDISON, N.J., Oct. 3, 2016 /PRNewswire/ -- ContraVir
Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company
focused on the development and commercialization of targeted
antiviral therapies, today announced that it will present at The
15th Annual BIO Investor Forum to be held October 18-19, 2016, at the Westin St. Francis,
San Francisco.
Chief Executive Officer, James
Sapirstein will provide an overview of the company's
business during live presentations, and will be available to
participate in one-on-one meetings with investors who are
registered to attend the conference.
Conference Details
|
Event:
|
|
The
15th Annual BIO Investor Forum
|
|
Date:
|
|
Tuesday, October 18,
2016
|
|
Time:
|
|
2 p.m. (Pacific
Time)
|
|
Location:
|
|
Westin St. Francis,
San Francisco
|
|
|
|
About ContraVir Pharmaceuticals
ContraVir is a
biopharmaceutical company focused on the development and
commercialization of targeted antiviral therapies with a specific
focus on developing a potentially curative therapy for hepatitis B
virus (HBV). The Company is developing two novel anti-HBV compounds
with complementary mechanisms of action: CMX157, a highly potent
analog of the successful antiviral drug tenofovir currently in
Phase 2a, which has demonstrated the potential for low, once a day
dosing compared to Viread® and decreased systemic
exposure, thereby potentially reducing renal and bone side effects;
and CRV431, a next generation cyclophilin inhibitor with a unique
structure that increases its potency and selective index against
HBV. ContraVir is also developing FV-100, an orally available
nucleoside analogue prodrug for the treatment of herpes zoster, or
shingles, in a Phase 3 clinical trial. In addition to direct
antiviral activity, FV-100 has demonstrated the potential to reduce
the incidence of debilitating shingles-associated pain known as
post-herpetic neuralgia (PHN) in a Phase 2 clinical study. For
more information visit www.contravir.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements may be identified by the use of
forward-looking words such as "anticipate," "believe," "forecast,"
"estimated" and "intend," among others. These forward-looking
statements are based on ContraVir's current expectations and actual
results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, substantial competition; our ability to continue as
a going concern; our need for additional financing; uncertainties
of patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. ContraVir does
not undertake an obligation to update or revise any forward-looking
statement. Investors should read the risk factors set forth in
ContraVir's Form 10-K for the year ended June 30, 2016 and other periodic reports filed
with the Securities and Exchange Commission.
For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations
sp@contravir.com; (732) 902-4028
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664
Claire LaCagnina (media)
clacagnina@tiberend.com; (212) 375-2686
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/contravir-to-present-at-the-15th-annual-bio-investor-forum-300337738.html
SOURCE ContraVir Pharmaceuticals, Inc.